Sotera Health reported a 6% increase in net revenues to $263 million for Q3 2023, but experienced a net loss of $14 million, or $0.05 per diluted share, due to a $35 million legal settlement and higher interest expenses. Adjusted EBITDA increased by 7% to $134 million, while Adjusted EPS decreased to $0.21. The company reaffirmed its 2023 outlook, anticipating results at the lower end of the previously announced range.
Net revenues increased by 6% to $263 million compared to Q3 2022.
Net loss was $14 million, or $0.05 per diluted share, including a $35 million legal settlement.
Adjusted EBITDA increased by 7% to $134 million compared to Q3 2022.
Adjusted EPS decreased to $0.21, driven by higher interest expense.
Sotera Health anticipates 2023 results will be at the lower end of its previously announced outlook due to ongoing market softness.
Visualization of income flow from segment revenue to net income